{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:02:06Z","timestamp":1789030926485,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The occurrence of dyspnea in patients with acute coronary syndrome (ACS) has always been considered a challenging diagnostic and therapeutic clinical scenario. Ticagrelor, a platelet receptor inhibitor, has beneficial effects in the prevention of ischemic events and mortality, but can cause dyspnea in ACS patients. In this study, we intend to investigate the prevalence of dyspnea in patients with ACS who are under treatment with ticagrelor. This prospective observational cohort study included 200 patients diagnosed with ACS from March 2020 to March 2022 and referred to the Cardiology Department of Modarres Hospital. After prescribing the medicine, the presence and severity of dyspnea were recorded daily according to the modified Borg dyspnea scale during hospitalization. Patients were followed up for 3 months after discharge, and the occurrence of dyspnea was investigated based on the characteristics of the patients. There were no major differences between groups in terms of gender, diabetes, hypertension, or smoking status. Most patients had normal lung auscultation, and the majority presented with unstable angina. Our results showed that 21.5% of patients experienced dyspnea, and 3% of patients stopped using drugs due to the severity of dyspnea. The time of the first attack varied from 1.5 to 36 hours after drug administration, and the maximum intensity of the first attack reached 7. The duration of the second attack varied from 2 to 22 days and was observed with a maximum intensity of 6. The age of patients was significantly higher in people who experienced dyspnea compared to those without dyspnea. Dyspnea is a common side effect in ACS patients receiving ticagrelor. The etiology of new-onset dyspnea in these patients can be complex and challenging to evaluate, as conventional factors did not appear to predict its occurrence. Given the significant therapeutic benefits of ticagrelor, discontinuation should only be considered for persistent and intolerable dyspnea associated with the medication. Further large-scale studies are warranted to better understand its clinical significance and to develop optimal management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048489","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:04:05Z","timestamp":1778745845000},"page":"e48489","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and predictors of dyspnea in acute coronary syndrome patients receiving ticagrelor: A prospective cohort study in Iran"],"prefix":"10.1097","volume":"105","author":[{"given":"Maryam","family":"Taherkhani","sequence":"first","affiliation":[{"name":"Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naimeh","family":"Kord","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adineh","family":"Taherkhani","sequence":"additional","affiliation":[{"name":"Department of Gasterointestinology, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Shirazi","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Medical School, Western University of Health Sciences, Pomona, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-9385","authenticated-orcid":false,"given":"Arian","family":"Tavasol","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/cells11061014","article-title":"Platelets, a key cell in inflammation and atherosclerosis progression.","volume":"11","author":"Huilcaman","year":"2022","journal-title":"Cells"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0735-1097(98)00635-4","article-title":"Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial.","volume":"33","author":"Ault","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260805","first-page":"e36335","article-title":"Efficacy, safety, and role of antiplatelet drugs in the management of acute coronary syndrome: a comprehensive review of literature.","volume":"15","author":"Abubakar","year":"2023","journal-title":"Cureus"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"e013263","DOI":"10.1161\/CIRCINTERVENTIONS.123.013263","article-title":"Antiplatelet de-escalation strategies in patients undergoing percutaneous coronary intervention.","volume":"17","author":"Spirito","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"e034529","DOI":"10.1161\/JAHA.124.034529","article-title":"Frailty and clinical outcomes of ticagrelor versus clopidogrel in older adults with acute myocardial infarction.","volume":"13","author":"Ko","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3892\/etm.2016.3224","article-title":"Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.","volume":"11","author":"Lu","year":"2016","journal-title":"Exp Ther Med"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.","volume":"32","author":"Storey","year":"2011","journal-title":"Eur Heart J"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ajem.2012.03.002","article-title":"Are there symptom differences in patients with coronary artery disease presenting to the ED ultimately diagnosed with or without ACS?","volume":"30","author":"Pelter","year":"2012","journal-title":"Am J Emerg Med"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.126.2.461","article-title":"Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events.","volume":"126","author":"Brieger","year":"2004","journal-title":"Chest"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R15-20260805","first-page":"e28","article-title":"Heart disease and stroke statistics--2014 update: a report from the American Heart Association.","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijcard.2014.02.028","article-title":"Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients.","volume":"173","author":"Gaubert","year":"2014","journal-title":"Int J Cardiol"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.167.2.211","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing.","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/ajrccm.167.10.950","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing.","volume":"167","author":"Ross","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvaa089","article-title":"Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome.","volume":"7","author":"Giannoni","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.3390\/app121910021","article-title":"Factors determining ticagrelor-induced dyspnea in patients with acute coronary syndrome.","volume":"12","author":"Tamakauskas","year":"2022","journal-title":"Appl Sci"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R25-20260805","first-page":"2514","article-title":"Dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention.","volume":"16","author":"Angiolillo","year":"2023","journal-title":"Cardiovasc Interv"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijcard.2015.03.417","article-title":"Ticagrelor related dyspnea in patients with acute coronary syndromes: incidence and implication on ticagrelor withdrawn.","volume":"187","author":"S\u00e1nchez-Galian","year":"2015","journal-title":"Int J Cardiol"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study.","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40256-015-0147-y","article-title":"One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.","volume":"15","author":"Simeone","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijcard.2010.08.035","article-title":"Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.","volume":"150","author":"Biondi-Zoccai","year":"2011","journal-title":"Int J Cardiol"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1160\/TH11-08-0586","article-title":"Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.","volume":"108","author":"Steiner","year":"2012","journal-title":"Thromb Haemost"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.","volume":"112","author":"Alexopoulos","year":"2014","journal-title":"Thromb Haemost"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11239-012-0838-z","article-title":"Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.","volume":"36","author":"Chatterjee","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.ijcard.2013.10.043","article-title":"Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.","volume":"170","author":"Deharo","year":"2013","journal-title":"Int J Cardiol"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijcard.2011.05.083","article-title":"Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.","volume":"150","author":"Passaro","year":"2011","journal-title":"Int J Cardiol"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"e012530","DOI":"10.1161\/JAHA.119.012530","article-title":"Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST\u2010segment\u2013elevation myocardial infarctions.","volume":"8","author":"Schmucker","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R36-20260805","first-page":"e46455","article-title":"Efficacy and safety profile of ticagrelor versus clopidogrel in percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS): a systematic review and meta-analysis.","volume":"15","author":"Maqbool","year":"2023","journal-title":"Cureus"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"180","author":"Turgeon","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.ijcard.2014.07.216","article-title":"First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea.","volume":"176","author":"Wu","year":"2014","journal-title":"Int J Cardiol"},{"issue":"suppl_F","key":"R39-20260805","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1093\/eurheartj\/suw034","article-title":"Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.","volume":"18","author":"Wang","year":"2016","journal-title":"Eur Heart J Suppl"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:02:32Z","timestamp":1785945752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048489","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2025-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}